(ISSN 2573-4407)
OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2024): Submission to First Decision: 7.6 weeks; Submission to Acceptance: 13.6 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)
Special Issue
Time to Talk Outcomes: New Models and Strategies for Chronic Psychotic and Depressive Disorders
Submission Deadline: October 31, 2025 (Open) Submit Now
Guest Editor
Adonis Sfera, MD
Chief of professional education at Patton State Hospital, California, United States
Research Interests: Psychiatry; clinical neurophysiology; schizophrenia; psychopathology; clinical psychiatry
About This Topic
For over six decades psychiatric treatment of depression and psychosis has been guided by the serotonin and dopamine hypotheses respectively. Yet, despite the advent of numerous antipsychotic and antidepressant drugs, the prevalence of both conditions has increased dramatically since the late 1980s. For example, depression remains the greatest cause of disability worldwide. Moreover, State hospitals are still standing as proof of concept that sustained recovery in schizophrenia, (measured by achieving the premorbid level of functioning without relapse) is rare. Indeed, less than 15% of patients with chronic psychotic disorders are employed at any time after the first psychotic episode.
As dopamine maintains the gray matter integrity, long-term exposure to dopamine blockers may result in brain volume reduction and decreased mitochondrial abundancy. Along this line, an antipsychotic drugs-related iatrogenic cognitive deficit was recently documented, suggesting that management of chronic psychosis could require non-dopamine depleting agents.
The present topic has emerged from the examination of data on novel antipsychotic drugs, the muscarinic agonists, which are devoid of dopamine receptor–blocking activity. Furthermore, a new schizophrenia paradigm, based on aryl hydrocarbon receptor, is further proof that novel, nonconventional antipsychotic strategies are gradually emerging to improve the outcome of both chronic psychosis and major depressive disorder.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Love in the Time of COVID: Psychiatric Outcomes Related to Oxytocin and the “Endocrine Organ”Abstract The COVID-19 pandemic was an eye-opener for many medical disciplines. It highlighted viral exploitation of physiological cellular processes, including endocytosis and cellular senescence. These pathways play an essential role in cancer, neurodegenerative disorders, and schizophrenia (SCZ). Oxytocin, commonly called the “love hormone,” [...] |
| 2023 |  |
|
| CiteScore | SJR | SNIP |
| 1.0 | 0.232 | 0.256 |
TOP
